Organogenesis Holdings Inc.

NASDAQ:ORGO

Drug Manufacturers - Specialty & Generic

Healthcare
$0.85 +3.21%

+$0.08 today

Market cap
$110.75M
Beta
1.33
P/E (TTM)
-1086.7
EPS (TTM)
-$0.00
52W Low $2.04High $7.08

Volume 0.86M

Average 1.49M

ORGO Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Organogenesis Holdings Inc.NASDAQ: ORGO

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $12.37M rose 96.9% year over year, ahead of the +70.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 76.4% from the prior quarter. Over 3 fiscal years it compounded at +14.3% a year.

Context

  • Depreciation & amortization amounted to 4.8% of revenue in FY2025, up 1.3 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +96.9% holds above the trailing-twelve-month pace of +70.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$12.37M+76.4% QoQ
Last fiscal yearDec 2025
$26.94M+58.2% YoY
LTMMar 2026
$33.03M+70.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+96.9%——
1 year+58.2%——
3-year CAGR+14.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
26.94M USD
Year-over-year change
+58.2%
4-year CAGR
+12.7%

Depreciation & Amortization vs competitors

How ORGO compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +70.8% is the highest of 10, against a peer median of -0.7%.
  • Depreciation & amortization amounts to 6.4% of revenue for ORGO, versus a peer median of 4.6%.
ORGO Competitors
Depreciation & Amortization for ORGO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$95.4M USD-8.8%-7.7%14.1%
SNDLSNDL Inc.LTM Mar 2026CA$56.2M CAD-0.2%+5.9%6.0%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$33.03M USD+70.8%+14.3%6.4%
VREXVarex Imaging CorporationLTM Apr 2026$27.1M USD-0.7%-6.8%3.2%
ANGOAngioDynamics, Inc.LTM Feb 2026$23.26M USD-13.2%-4.2%7.4%
EOLSEvolus, Inc.LTM Mar 2026$9.28M USD+53.3%+32.9%3.1%
BCYCBicycle Therapeutics plcLTM Mar 2026$5.92M USD-17.6%+20.3%9.3%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$1.12M USD-32.0%-8.2%—
SIGASIGA Technologies, Inc.LTM Mar 2026$577.25K USD+7.8%+2.8%0.6%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$106K USD+19.1%-40.6%0.0%
MNPRMonopar Therapeutics Inc.LTM Mar 2026$0 USD———
Peer median (excluding ORGO) —-0.7%-4.2%4.6%

Competitors are the stored peer set for ORGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue467.36M450.89M433.14M482.04M563.03M
Cost of Revenue114.2M105.02M106.48M115.74M137.52M
Gross Profit353.16M345.87M326.66M366.3M425.51M
Gross Margin75.6%76.7%75.4%76.0%75.6%
Research & Development30.74M39.76M44.38M50.27M44.54M
Selling, General & Admin250.2M283.81M269.75M294.51M326.24M
Operating Expenses280.94M323.57M314.13M367.59M369.64M
Depreciation & Amortization16.68M18.03M23.45M17.03M26.94M
EBITDA87M40.32M36.03M15.76M73.91M
EBITDA Margin18.6%8.9%8.3%3.3%13.1%
Operating Income72.22M22.3M12.53M(1.28M)55.87M
Operating Margin15.5%4.9%2.9%-0.3%9.9%
Interest Income00002.28M
Interest Expense7.24M2.01M2.19M1.54M0
Other Income / Expenses(9.13M)(2.02M)(2.13M)(1.52M)(8.9M)
Income Before Tax63.09M20.28M10.39M(2.81M)46.97M
Pre-Tax Margin13.5%4.5%2.4%-0.6%8.3%
Income Tax Expense(31.12M)4.75M5.45M(3.67M)9.94M
Net Income94.2M15.53M4.95M861K37.03M
Net Margin20.2%3.4%1.1%0.2%6.6%
EPS (Basic)0.730.120.04(0.01)0.16
EPS (Diluted)0.700.120.04(0.01)0.15
Weighted Avg Shares128.33M130.07M131.23M131.67M126.74M
Weighted Avg Shares (Diluted)133.66M132.38M132.75M131.67M130.25M

Organogenesis Holdings Inc.

NASDAQ:ORGO

Intrinsic Alpha fair value

Locked

Current Price

$0.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.